Optimization of the protocol for the assembly of recombinant adenoassociated serotype 2 viruses for the delivery of African swine fever virus genes into mammalian cells

African swine fever (ASF) is a highly contagious viral disease of the Suidae family representatives, the mortality rate in primary foci of which reaches 100 %. To date, no specific means of preventing ASF have been developed. Despite the fact that researchers have proposed various methods for creating candidate vaccines against ASF, the issue of developing alternative antigenic variants with low reactogenicity and high immunogenicity is still relevant. It is known that the production of recombinant adeno-associated virus, a potential tool for delivering ASF virus target genes into mammalian cells, is influenced by many factors, in particular, the cell line, expression system, cell culture conditions after transfection, and the quality of the initial plasmid DNA. This work presents the results of optimization of the assembly protocol for recombinant AAV2 carrying the major capsid protein gene of the ASFV B646L as a model cargo. During the research, it was established that the protocol used allows to achieve a veritable virus titer of (2.45 ± 0.17) × 107 viral particles per μl, while the share of fully assembled viral capsids accounts for up to (79.3 ± 2.3) % of all genomic copies. When assessing the potential cytopathogenic effect of recombinant AAV2 on target cells (SPEV, porcine MSCs), it was found that high MOI (up to 10,000 viral particles per cell) does not lead to an increase in the proportion of apoptotic cells. The functionality of the developed AAV2-based construct was confirmed: in the lysates of transduced cells, the mature p72 protein with a molecular weight of 73 kDa was detected, specifically reacting in a western blot with hyperimmune pig serum. Our data confirm the potential of AAV2 as a tool for delivering ASF virus genes into porcine cells, which makes it a promising basis for the design of candidate vaccines.

1. Makarov V.V. African swine fever. Russian veterinary journal. 2018; 6:15-19. DOI: 10.32416/article_5c050abbcf8d70.94861250. (In Russ.)

2. Gruzdev K.N., Zakutsky N.I., Diev V.I. African swine fever: current status, epizootology and control measures (analytical review). The Veterinarian. 2017; 5: 3-10. (In Russ.)

3. Aliper T.I., Zaberezhny A.D., Grebennikova T.V. African swine fever in the Russian Federation. Problems of virology. 2012; S1: 127-136. (In Russ.)

4. Makarov V.V., Barsukov Yu.I. Epizootic process of African swine fever. Current issues in veterinary biology. 2022; 4(56): 8-14. DOI: 10.24412/2074-5036-2022-4-8-14. (In Russ.)

5. Kolbasov D.V. African swine fever: the creation of a vaccine is urgent. Russian animal husbandry. 2020; 7: 29-32. DOI: 10.25701/ZZR.2020.48.46.008. (In Russ.)

6. Efimova M.A., Galeeva A.G., Khamidullina A.I., Ravilov R.Kh. Analysis of immunodominant peptides of the African swine fever virus for the design of candidate vaccines. Agrarian Science. 2023; 3: 40-45. DOI: 10.32634/0869-8155-2023-368-3-40-45. (In Russ.)

7. Ravilov R.K., Rizvanov A.A., Mingaleev D.N., Galeeva A.G., Zakirova E.Yu., Shuralev E.A., Rutland C.S., Khammadov N.I., Efimova M.A. Viral Vector Vaccines Against ASF: Problems and Prospectives. Front Vet Sci. 2022; 9: 830244. DOI: 10.3389/fvets.2022.830244.

8. Wang D., Tai P.W.L., Gao G. Adenoassociated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019; 18(5): 358-378. DOI: 10.1038/s41573-019-0012-9.

9. Usman N.Yu., Rebrikov D.V. Recombinant adeno-associated viruses as a means of gene delivery for use in molecular medicine. Bulletin of RSMU. 2021; 5:5-11. DOI: 10.24075/vrgmu.2021.051. (In Russ.)

10. Oziolor E.M., Kumpf S.W., Qian J., Gosink M., Sheehan M., Rubitski D.M., Newman L., Whiteley L.O., Lanz T.A. Comparing molecular and computational approaches for detecting viral integration of AAV gene therapy constructs. Mol Ther Methods Clin Dev. 2023; 29: 395-405. DOI: 10.1016/j.omtm.2023.04.009.

11. Grieger J.C., Soltys S.M., Samulski R.J. Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Mol Ther. 2016; 24(2): 287–97. DOI: 10.1038/mt.2015.187.

12. Ryabova E.I., Derkaev A.A., Esmagambetov I.B., Shcheblyakov D.V., Dovgiy M.A., Byrikhina D.V., Prokofiev V.V., Chemodanova I.P. Comparison of various technologies for producing recombinant adenoassociated virus on a laboratory scale. BIOpreparations. Prevention, diagnosis, treatment. 2021; 21(4): 266–278. DOI: 10.30895/2221-996X-2021-21-4-266-278. (In Russ.)

13. Ravilov R., Galeeva A., Frolov G., Efimova M., Zakirova A., Rizvanov A., Hisamutdinov A., Garipov L., Mingaleev D. Efficient delivery of the immunodominant genes of African swine fever virus by adenoassociated virus serotype 2. Vet World. 2023; 12(16): 2425-2430. DOI: 10.14202/vetworld.2023.2425-2430.

14. De Villiers E.P., Gallardo C., Arias M., da Silva M., Upton C., Martin R., Bishop R.P. Phylogenomic analysis of 11 complete African swine fever virus genome sequences. Virology. 2010; 400(1):128-136. DOI: 10.1016/j.virol.2010.01.019.

15. Stender S., Murphy M., O'Brien T., Stengaard C., Ulrich-Vinther M., Søballe K., Barry F. Adeno-associated viral vector transduction of human mesenchymal stem cells. Eur Cell Mater. 2007; 13: 93-99. DOI: 10.22203/ecm.v013a10.

16. Sereda A.D., Kolbasov D.V. African swine fever virus proteins. Scientific journal of KubSAU. 2012; 77: 21-37. (In Russ.)